161 related articles for article (PubMed ID: 21194444)
1. Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment--case report.
Hsieh CH; Chang HT; Lin SC; Chen YJ; Wang LY; Hsieh YP; Chen CA; Chong NS; Lin SL; Chen CY; Shueng PW
BMC Cancer; 2010 Dec; 10():696. PubMed ID: 21194444
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.
Iyengar P; Kavanagh BD; Wardak Z; Smith I; Ahn C; Gerber DE; Dowell J; Hughes R; Abdulrahman R; Camidge DR; Gaspar LE; Doebele RC; Bunn PA; Choy H; Timmerman R
J Clin Oncol; 2014 Dec; 32(34):3824-30. PubMed ID: 25349291
[TBL] [Abstract][Full Text] [Related]
3. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
[TBL] [Abstract][Full Text] [Related]
4. Patterns of CT lung injury and toxicity after stereotactic radiotherapy delivered with helical tomotherapy in early stage medically inoperable NSCLC.
Arcangeli S; Agolli L; Portalone L; Migliorino MR; Lopergolo MG; Monaco A; Dognini J; Pressello MC; Bracci S; Donato V
Br J Radiol; 2015 Apr; 88(1048):20140728. PubMed ID: 25645106
[TBL] [Abstract][Full Text] [Related]
5. Radiation recall pneumonitis induced by erlotinib after palliative thoracic radiotherapy for lung cancer: Case report and literature review.
Awad R; Nott L
Asia Pac J Clin Oncol; 2016 Mar; 12(1):91-5. PubMed ID: 26846159
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib-induced rash spares previously irradiated skin.
Lips IM; Koster ME; Houwing RH; Vonk EJ
Strahlenther Onkol; 2011 Aug; 187(8):499-501. PubMed ID: 21789741
[TBL] [Abstract][Full Text] [Related]
7. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
Makris D; Scherpereel A; Copin MC; Colin G; Brun L; Lafitte JJ; Marquette CH
BMC Cancer; 2007 Aug; 7():150. PubMed ID: 17683587
[TBL] [Abstract][Full Text] [Related]
8. Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer.
Nanda A; Dias-Santagata DC; Stubbs H; O'Hara CJ; Zaner KS; Lynch TJ; Willers H
Clin Lung Cancer; 2008 Sep; 9(5):285-7. PubMed ID: 18824451
[TBL] [Abstract][Full Text] [Related]
9. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Tammaro KA; Baldwin PD; Lundberg AS
J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
[TBL] [Abstract][Full Text] [Related]
10. Comparison of I
Zhang Z; Mao H; Wang X; Sheng W
J Cancer Res Ther; 2020; 16(7):1560-1568. PubMed ID: 33565500
[TBL] [Abstract][Full Text] [Related]
11. Analysis of dose distribution and risk of pneumonitis in stereotactic body radiation therapy for centrally located lung tumors: a comparison of robotic radiosurgery, helical tomotherapy and volumetric modulated arc therapy.
Kannarunimit D; Descovich M; Garcia A; Chen J; Weinberg V; Mcguinness C; Pinnaduwage D; Murnane J; Gottschalk AR; Yom SS
Technol Cancer Res Treat; 2015 Feb; 14(1):49-60. PubMed ID: 24325136
[TBL] [Abstract][Full Text] [Related]
12. Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy.
Zhuang H; Yuan Z; Chang JY; Wang J; Pang Q; Zhao L; Wang P
J Thorac Oncol; 2014 Jun; 9(6):882-5. PubMed ID: 24828665
[TBL] [Abstract][Full Text] [Related]
13. Repeat stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell lung cancer and lung metastasis after first SBRT.
Ogawa Y; Shibamoto Y; Hashizume C; Kondo T; Iwata H; Tomita N; Ogino H
Radiat Oncol; 2018 Jul; 13(1):136. PubMed ID: 30055636
[TBL] [Abstract][Full Text] [Related]
14. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
[TBL] [Abstract][Full Text] [Related]
16. Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.
Um SJ; Lee SK; Yang DK; Son C; Roh MS; Kim KN; Lee KN; Choi PJ
Clin Respir J; 2009 Jul; 3(3):181-4. PubMed ID: 20298401
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
18. Radiation recall pneumonitis caused by erlotinib after palliative definitive radiotherapy.
Onal C; Abali H; Koc Z; Kara S
Onkologie; 2012; 35(4):191-4. PubMed ID: 22488089
[TBL] [Abstract][Full Text] [Related]
19. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study.
Wang X; Zeng Z; Cai J; Xu P; Liang P; Luo Y; Liu A
BMC Cancer; 2021 Apr; 21(1):482. PubMed ID: 33931014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
